A study of Pumitamig compared to Durvalumab after concurrent chemoradiotherapy in participants with unresectable stage III non-small cell lung cancer (NSCLC) (ROSETTA Lung-201)

Kriterien zur Teilnahme
- Participants must have a histologically or cytologically confirmed diagnosis of unresectable stage III non-small cell lung cancer (NSCLC) - Participants must have received at least 2 cycles of platinum-based concurrent chemotherapy (a total radiation dose of at least 54 Gy). - Participants must not have disease progression (PD) after treatment with concurrent chemoradiotherapy (CCRT). - Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. (BASEC)

Ausschlusskriterien
- Participants with non-squamous histology must not have documented epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements. - Participants must not have an active autoimmune disease. - Participants must not have significant cardiovascular impairment such as uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary artery disease (within 6 months prior to randomization), ventricular arrhythmias, severe thrombotic or embolic events or severe hemorrhagic events within 6 months prior to randomization or significant risk of pulmonary hemorrhage. - Participants must not have advanced/clinically significant lung disease (within 6 months prior to randomization) or a history of interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids (≥ grade 2), or current or suspected ILD or pneumonitis. - Participants must not have received prior cancer therapy (other than CCRT) for locally advanced stage III disease. - Additional inclusion/exclusion criteria defined in the study protocol apply. (BASEC)